Incyte’s Opzelura wins positive CHMP opinion for moderate atopic dermatitis in Europe
The positive opinion moves ruxolitinib cream closer to a broader European label for adults inadequately controlled by standard topical therapies, opening a potential treatment position between conventional creams and systemic medicines.
